Who are Oral anticoagulation therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pradaxa, Standard dose oral anticoagulant, Low dose oral anticoagulant, Direct-acting oral anticoagulation, Rivaroxaban, Dabigatran, Warfarin or coumadin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-anticoagulation-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Oral anticoagulation therapy — Competitive Intelligence Brief

Oral anticoagulation therapy (Oral anticoagulation therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral anticoagulant. Area: Cardiovascular.

marketed Oral anticoagulant Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Oral anticoagulation therapy (Oral anticoagulation therapy) — China National Center for Cardiovascular Diseases. Oral anticoagulation therapy prevents blood clot formation by inhibiting coagulation cascade factors, reducing thromboembolism risk.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral anticoagulation therapy TARGET	Oral anticoagulation therapy	China National Center for Cardiovascular Diseases	marketed	Oral anticoagulant
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	marketed	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Standard dose oral anticoagulant	Standard dose oral anticoagulant	Korea University Guro Hospital	marketed	Vitamin K antagonist (warfarin-type oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Low dose oral anticoagulant	Low dose oral anticoagulant	Korea University Guro Hospital	marketed	Oral anticoagulant
Direct-acting oral anticoagulation	Direct-acting oral anticoagulation	Hospital Universitario La Fe	marketed	Direct-acting oral anticoagulant (DOAC)	Factor IIa or Factor Xa
Rivaroxaban, Dabigatran	Rivaroxaban, Dabigatran	University Hospital, Grenoble	marketed	Direct oral anticoagulant (DOAC)	Factor Xa (rivaroxaban); Thrombin/Factor IIa (dabigatran)
Warfarin or coumadin	Warfarin or coumadin	Ottawa Heart Institute Research Corporation	marketed	Vitamin K antagonist (oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral anticoagulant class)

China National Center for Cardiovascular Diseases · 1 drug in this class
Korea University Guro Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral anticoagulation therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-anticoagulation-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab